In contrast, It is currently uncertain what therapy would best suit patients with Immunotype-2 tumors characterized by Th2/Th17 responses, infrequent LN involvement, an intermediate prognosis, and increased tumor purity; further investigation is required to identify potential immunotherapy targets associated with the immune complement cascade and GATA3. Here, GATA3 is linked to neoplasm.